GT Biopharma, Inc. cotiza a 6.50 USD y tiene una capitalización bursátil de $13M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
GT Biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of immuno-oncology products based on its Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) platforms. It develops GTB-3650, which is in phase 1 trials that target C…
| Periodo | 2026-08 | 2026-05 | 2026-03 | 2025-11 |
|---|---|---|---|---|
| Real | $-3.00 | $-2.75 | $-121.00 | $-20.75 |
| Estimado | $-2.00 | $-2.00 | $-5.50 | $-9.50 |
| Sorpresa | -50.0% | -37.5% | -2100.0% | -118.4% |
| Métrica | GTBP | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | -490.0% | -40.4% | -449.6% |
| ROA | -349.8% | -32.0% | -317.8% |
| Current Ratio | 3.50 | 2.84 | +0.66 |
| Debt / Equity | — | 0.28 | — |